Adv Ther (2017) 34:2566–2584 DOI 10.1007/s12325-017-0644-2 REVIEW Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER22 Advanced Breast Cancer . . . . Zhou Zhou Derek H. Tang Jipan Xie Rajeev Ayyagari Eric Wu Polly A. Niravath Received: August 3, 2017 / Published online: November 16, 2017 Springer Healthcare Ltd., part of Springer Nature 2017 ET ? TT, and comparisons between the two ABSTRACT were summarized from the identiﬁed trials. Results: A total of 11 studies (representing 6 Introduction: A major treatment goal for RCTs) were identiﬁed. The study populations advanced breast cancer (ABC) is to maintain or included ﬁrst-line (5 studies) and ET-failure ideally improve patient quality of life (QoL). settings (6 studies). Across settings, global Given the changing disease landscape, this sys- health status (GHS) maintained or deteriorated tematic literature review (SLR) aims to assess the slightly on these treatments during the trial impact of endocrine therapies (ET), including period. Time to deterioration (TTD) in QoL ET monotherapy (ET mono) and ET combined measured by GHS was analyzed in 6 studies and with targeted therapy (ET ? TT), on QoL of 4
Advances in Therapy – Springer Journals
Published: Nov 16, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud